BLUDE Immucor (MM)

Lerach Coughlin Stoia Geller Rudman & Robbins LLP ("Lerach Coughlin") (http://www.lerachlaw.com/cases/Immucor/) today announced that a class action has been commenced in the United States District Court for the Northern District of Georgia on behalf of purchasers of Immucor, Inc. ("Immucor") (NASDAQ:BLUDE) common stock during the period between January 7, 2005 and August 29, 2005 (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from August 31, 2005. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, William Lerach or Darren Robbins of Lerach Coughlin at 800/449-4900 or 619/231-1058, or via e-mail at wsl@lerachlaw.com, or at 401 B Street, Suite 1600, San Diego, CA 92101. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.lerachlaw.com/cases/Immucor/. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. The complaint charges Immucor and certain of its officers and directors with violations of the Securities Exchange Act of 1934. During the Class Period, defendants caused Immucor's shares to trade at artificially inflated levels by issuing a series of materially false and misleading statements regarding the Company's financial statements, business and prospects. This caused the Company's stock to trade as high as $34.98 per share. Defendants took advantage of this artificial inflation selling 139,500 shares of their Immucor stock for proceeds of $4.2 million. On August 26, 2005, Immucor announced a formal Securities and Exchange Commission investigation into payments made by Immucor's Italian subsidiary in October 2003 to a physician connected to a hospital with which Immucor did business. Then, on August 29, 2005, after the market closed, the Company announced that it had revised its net income for fiscal 2005 to account for a previously unrecorded accrual for employee bonuses and furthermore made an announcement that it had accepted the resignation of defendant Steven Ramsey from the post of Chief Financial Officer. On this news, Immucor's stock collapsed to as low as $22.67 per share before closing at $24 per share on volume of 6.2 million shares. Plaintiff seeks to recover damages on behalf of all purchasers of Immucor common stock during the Class Period (the "Class").